Skip to content
LONDON/AMSTERDAM (Reuters) - Prosus held firm on its $6.3 billion offer to buy Just Eat on Monday as it argued the merits of its bid versus one from Takeaway.com for the British online takeaway delivery firm. "We actually believe that financial markets are under- estimating the cost of implementing the transformation Just Eat requires to protect its market position and to capitalise on its long-term opportunity," Prosus CEO Bob Van Dijk said. Prosus has weighed in with an unsolicited cash offer of $6.3 billion, or 710 pence per share, for Just Eat....
The simplest way to invest in stocks is to buy exchange traded funds. But investors can boost returns by picking......
OPEC and allied oil producers will probably extend a deal to limit crude supply but are unlikely to deepen their cuts, Oman's energy minister said on Monday, as the United Arab Emirates said it was not worried about long-term growth in oil demand. "Extension probably, (deeper) cuts I think unlikely unless things happen in the next couple of weeks," the energy minister of non-OPEC Oman, Mohammed bin Hamad al-Rumhy, told reporters at an energy conference in the UAE capital Abu Dhabi....
Lance H. Batchelor has been the CEO of Saga plc (LON:SAGA) since 2014. First, this article will compare CEO......
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will......
Dividend paying stocks like Prosegur Cash, S.A. (BME:CASH) tend to be popular with investors, and for good reason......
Roche's bid to rival Biogen and Novartis in treating spinal muscular atrophy (SMA) got a lift on Monday when the Swiss drugmaker said its drug risdiplam improved motor function of patients in a key study. Roche, which plans to seek approval for the investigational medicine this year, said its SUNFISH trial demonstrated statistically significant improvements in patients aged 2-25 years with Type 2 or 3 SMA, compared to a placebo. Biogen's Spinraza, approved in 2016, lists at $750,000 in year one and $375,000 thereafter, while Novartis's Zolgensma is the costliest one-time treatment at $2.1 million....
